Data mining approach to estimate the duration of drug therapy from longitudinal electronic medical records by Montvida, Olga et al.
Send Orders for Reprints to reprints@benthamscience.ae
The Open Bioinformatics Journal , 2017, 10, 1-15 1
The Open Bioinformatics Journal
Content list available at: www.benthamopen.com/TOBIOIJ/
DOI: 10.2174/1875036201709010001
RESEARCH ARTICLE
Data  Mining  Approach  to  Estimate  the  Duration  of  Drug  Therapy
from Longitudinal Electronic Medical Records
Olga Montvida1,2, Ognjen Arandjelović3, Edward Reiner4 and Sanjoy K. Paul5,*
1Clinical Trials and Biostatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia
2School  of  Biomedical  Sciences,  Institute  of  Health  and  Biomedical  Innovation,  Faculty  of  Health,  Queensland
University  of  Technology,  Brisbane,  Australia
3School of Computer Science, University of St. Andrews, St. Andrews, United Kingdom
4Smart Analyst Inc., New York, Unites States of America
5Melbourne EpiCentre, University of Melbourne and Melbourne Health, Melbourne, Australia
Received: March 27, 2017 Revised: May 06, 2017 Accepted: May 12, 2017
Abstract:
Background:
Electronic Medical Records (EMRs) from primary/ ambulatory care systems present a new and promising source of information for
conducting clinical and translational research.
Objectives:
To address the methodological and computational challenges in order to extract reliable medication information from raw data which
is often complex, incomplete and erroneous. To assess whether the use of specific chaining fields of medication information may
additionally improve the data quality.
Methods:
Guided by a range of challenges associated with missing and internally inconsistent data, we introduce two methods for the robust
extraction of patient-level medication data. First method relies on chaining fields to estimate duration of treatment (“chaining”),
while second disregards chaining fields and relies on the chronology of records (“continuous”). Centricity EMR database was used to
estimate treatment duration with both methods for two widely prescribed drugs among type 2 diabetes patients: insulin and glucagon-
like peptide-1 receptor agonists.
Results:
At individual patient level the “chaining” approach could identify the treatment alterations longitudinally and produced more robust
estimates  of  treatment  duration  for  individual  drugs,  while  the  “continuous”  method  was  unable  to  capture  that  dynamics.  At
population  level,  both  methods  produced  similar  estimates  of  average  treatment  duration,  however,  notable  differences  were
observed at individual-patient level.
Conclusion:
The proposed algorithms explicitly identify and handle longitudinal erroneous or missing entries and estimate treatment duration
with specific drug(s) of interest, which makes them a valuable tool for future EMR based clinical and pharmaco-epidemiological
studies. To improve accuracy of real-world based studies, implementing chaining fields of medication information is recommended.
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1. INTRODUCTION
The electronic medical records (EMRs) and the administrative data from the primary/ambulatory care systems are
increasingly  being  used  in  epidemiological  [1  -  3],  pharmaco-epidemiological  [4  -  6],  pharmaco-vigilance  [7  -  9],
clinical outcome [5, 10 - 12], health economic [13, 14] and public health related studies [15 - 18]. Analyses of large
primary care based EMRs from various countries, most notably from UK, USA and Sweden, have provided significant
insight into the effectiveness of changes in health care practices/polices on overall disease and health management costs
[3, 15, 19, 20], in addition to population level evidences on the safety and effectiveness of various therapies and the
association of disease-related risk factors on long-term outcomes [5, 6, 18, 21 - 23]. Increasing use of such large real-
world patient-level data is illustrated well by the sixfold increase in EMR based published studies since 2000 [10, 24].
In structured EMRs, especially from the primary/ambulatory care systems, comprehensive patient level data are
captured on different domains simultaneously and stored in the form of relational database [25, 26]. Representative
examples include the UK Clinical Practice Research Database and CentricityTM EMR (CEMR) database of USA [27,
28].  The  extraction,  quality  control  and  management  of  such  voluminous  longitudinal  data  under  individual  study
protocols is highly methodologically and computationally involved, and challenging from data mining and analytical
viewpoints [22, 29]. Data science generally considers that data preparation tasks consume about 80% of total project
timeline leaving only 20% for ultimate analysis itself [30, 31]. Data completeness, systematic biases, reproducibility
and quality are some of the notable limitations in such databases [18, 29, 32].
Most EMR databases capture large amounts of detailed information on medications provided to individuals over
time, while specific form in which this information is stored varies from database to database [26]. It is usually possible
to obtain the drug class, specific brand name within the corresponding class, prescription dates, dosage, and number of
refills [32]. However, a significant number of entries for an individual prescription may be missing or contain errors.
The problem with information completeness can also arise when the medication nomenclature is not correctly matched
[29].
Clinical  and  pharmaco-epidemiological  studies,  which  rely  on  the  data  from EMRs,  are  often  interested  in  the
effectiveness of specific therapies,  therapeutical  dynamics,  treatments with concomitant medications,  and durations
thereof in specific disease areas. Such real-world analysis provides an extremely valuable means for the understanding
of drug utilization patterns, treatment initiation periods following the diagnosis of a disease, the effectiveness of specific
therapies on disease-related risk factors, and possible associations of therapies with long-term outcomes [1, 6]. These
studies warrant appropriate extraction of longitudinal information on prescriptions or medications at individual patient
level, inappropriate extraction of the data may result in misleading inferences reported [33 - 35]. Generally, pharmaco-
epidemiological studies do not estimate treatment duration, but only account for the fact of one or more prescriptions
for a particular drug(s) [36, 37]. Some studies calculated medication duration by extracting first prescription date from
the  last  prescription  date  [38,  39],  and  only  few  studies  additionally  considered  a  drug  being  discontinued  if  the
subsequent prescription was not refilled within the expected time of drug coverage [40, 41]. While some studies have
discussed  the  challenges  in  the  analysis  of  medication  data  from EMRs [18,  42],  to  the  best  of  our  knowledge  no
existing study has analysed the quality, consistency, and completeness of EMR prescription information, nor proposed a
practical algorithm able to extract salient medication information from large and complex longitudinal data sets [43].
The aims of this explanatory and methodological study are (1) to discuss and analyse the most pressing challenges
encountered by computer based methods in the process of extracting and aggregating longitudinal medication data from
EMRs, (2) to describe two algorithms to extract prescription information of individual therapies and to estimate the
corresponding duration of treatment, and (3) to discuss how estimates of individual medication duration are affected by
the choice of the study design. The effectiveness of algorithms is compared is on a cohort of patients with a clinical
diagnosis of type 2 diabetes (T2DM) using a real-world EMR database collected across the USA.
2. MATERIALS AND METHODS
2.1. Centricity Electronic Medical Records
The  CEMR  database  contains  more  than  40  million  patients’  clinical/treatment  records  from  1995.  CEMR
represents 49 US states and a variety of ambulatory medical practices, including solo practitioners, community clinics,
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academic medical centres, and large integrated delivery networks. The database has been extensively used for academic
research  worldwide  [3,  37,  44  -  47].  The  CEMR database  consists  of  over  30,000  health  care  providers,  of  whom
approximately  70%  are  primary  care  providers.  For  both  insured  and  uninsured  patients,  this  database  contains
comprehensive  patient-level  information  on  many  aspects  including  demographic  information,  laboratory  results,
history  of  diseases,  clinical  diagnosis  of  symptoms/  diseases,  vital  signs,  history  of  medications  and  detailed
information on the ongoing medications. For this study we used longitudinal information from January 1995 to October
2014.
2.2. Medication Data in Centricity EMR database
The  medications  taken  by  an  individual  (medication  domain)  and  the  prescriptions  for  drugs  provided  to  the
individuals by the service provider registered within the EMR system (prescription domain) are extensively documented
in the database by means of three tables: medication dimension (MD), medication fact (MF) and prescription fact (PF).
The MF and PF belong to the medication and prescription domains respectively. The MF may include a broader list of
all  medications  that  a  patient  is  taking  including  over  the  counter  medications,  herbal  remedies  and  medications
prescribed by a provider that may be out of the EMR network. MD is linked to both MF and PF. Each record in the MD
contains information on individual drug, which includes the National Drug Code (NDC) and Generic Product Identifier
(GPI), as well as the four ordered attributes derived from the GPI such as generic drug names. The MD also includes the
medication doses corresponding to different brands’ products, identified by a unique medication key value assigned to
each record.
The entries  in  MF capture individual  patient’s  medication prescription history and active prescriptions from all
practitioners including the service provider registered within EMR system. It contains several special fields to track
longitudinal patterns, such as active medication flag, which indicates if a patient was taking the drug at the database
extraction moment. Active medication list is identified by records with value “Y” of active flag. The chain identification
(ID) values facilitate tracking of treatment alterations (including the addition of new medications) over time, with the
related chain sequence values which track medication adjustments within the same chain ID. The initiation (‘start’) and
cessation  (’stop’)  dates  associated  with  different  treatments  are  also  stored  in  the  MF.  However  we  found  that  the
corresponding values are missing with alarming frequencies: 67% of the cases for the former and 11% for the latter.
Also, some of the start and stop date entries could be erroneous, such as stop date preceding start date. An excerpt from
the MF for an individual patient is shown in Table 1.
Table 1. Snapshot of MF table – treatment intensification.
GPI category 4 Medication key (M) Patient key (P) Create date
(C)
Start date
(B)
Stop date
(S)
Active
flag (F)
Chain ID
(H)
Chain
seq (G)
METFORMIN HCL 41467 288859 6-May-09 6-May-09 N 307667619 0
METFORMIN HCL 41467 288859 11-Jun-10 11-Jun-10 N 307667619 1
METFORMIN HCL 41467 288859 25-Apr-11 11-Jun-10 25-Apr-11 N 307667619 2
LIRAGLUTIDE 3347202 288859 25-Apr-11 25-Apr-11 N 812855070 0
LIRAGLUTIDE 3347202 288859 10-May-11 10-May-11 N 812855070 1
LIRAGLUTIDE 3347202 288859 10-May-11 10-May-11 N 820957274 0
LIRAGLUTIDE 3347202 288859 14-Dec-11 10-May-11 14-Dec-11 N 820957274 1
LIRAGLUTIDE 3347202 288859 14-Dec-11 10-May-11 14-Dec-11 N 812855070 2
INSULIN GLARGINE 682327 288859 27-Feb-12 N 1092145628 0
INSULIN ISOPHANE HUMAN 682834 288859 27-Feb-12 N 1092145627 0
INSULIN GLARGINE 682327 288859 26-Sep-12 26-Sep-12 N 1092145628 1
INSULIN ISOPHANE HUMAN 682834 288859 14-Nov-12 N 1092145627 1
INSULIN GLARGINE 682327 288859 14-Nov-12 Y 1092145628 2
INSULIN LISPRO (HUMAN) 682825 288859 26-Feb-14 26-Feb-14 Y 1092145627 2
The entries in the PF capture the prescription date and the associated number of refills only for medications that
have been prescribed by the responsible provider within the EMR network. The MF dataset contains a broader set of
entry sources, moreover the form of recording potentially comprises more details than corresponding data in the PF.
Nevertheless it was determined that PF may contain unique entries that are not stored in MF. Therefore, the MF was
considered as the primary source of medication information and the PF as a complimentary one.
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3. METHODS
In this section, we introduce a novel algorithm for mining large-scale longitudinal EMRs with the ultimate goal of
estimating the duration of treatment of a particular individual with a drug(s) of interest. The first method we introduce
(“chaining”) relies on chain ID and chain sequence values recorded in the MF. This feature of the approach allows to
account for treatments which include alternative drug use. To assess the importance and power of longitudinal chain
information, we also describe a modification of the “chaining” method (“continuous”) which disregards chain ID and
chain sequence values, and instead relies only on the chronology of patient’s records of particular drug(s). In the current
literature, the latter approach is used more frequently.
3.1. Data Pre-processing: Auxiliary Fields
Although erroneous entries generally cannot be identified, various types of global consistency rules may be applied
to reduce the error. Chronology of the events may be corrected by incorporating two additional fields: patient’s last
available follow-up date and patient’s date of birth (DOB).
CEMR database stores last available follow-up date for each patient. As initial data pre-processing step, erroneous
follow-up  date  entries  were  identified  and  corrected  by  the  latest  record  creation  dates  of  all  activities  within  the
database for corresponding patients.
Similar to many anonymized EMRs, the exact DOB was not available within CEMR. Simple procedure was applied
to approximate DOB:
Obtain multiple DOB estimates per patient by subtracting reported ‘valid’ age from the record creation date for1.
all activities within the database. CEMR groups patients older than 80 years under a single age key. The non-
missing age data and the non 80+ age keys were considered as ‘valid’ age entries.
Approximate DOB as minimum of all estimates from Step 1.2.
For patients without reported activities estimate DOB from the dataset containing demographic information by3.
subtracting reported ‘valid’ age from the database extraction date.
The parameters for the mathematical formulations are identified in the Table 2 below.
Table 2. Mathematical Formulation
Scalars
n number of records in MF table
k number of records in PF table
sd standard prescription duration for individual drug
mx maximal number of prescription refills for individual drug
u number of unique patient keys in the cohort of interest
Sets
PS = {ps1,ps2,…… psu} set of unique patient keys in the cohort of interest
V set of missing values
MS set of medication keys of selected drug(s)
FY = {fi|fi = "Y", i = } set of active drugs
MF={M,P,C,B,S,F,H,G} dataset
M = (m1, m2,... ,mn)
T medication keys for drugs
P = (p1, p2,... ,pn)
T patient keys
C = (c1, c2,... ,cn)
T record creation dates
B = (b1, b2,... ,bn)
T start dates of individual records
S = (s1, s2,... ,sn)
T stop dates of individual records
F = (f1, f2,... ,fn)
T active medication flag values
H = (h1, h2,... ,hn)
T chain identification values
G = (g1, g2,... ,gn)
T chain sequence values
PF={M,P,C,B,R} dataset
M = (m1, m2,... ,mk)
T medication keys for individual prescriptions
P = (p1, p2,... ,pk)
T patient keys
1, 𝑛
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C = (c1, c2,... ,ck)
T record creation date
B = (b1, b2,... ,bk)
T prescription dates
R = (r1, r2,... ,rk)
T number of refills for individual prescription
The scalars sd and mx may be defined on the basis of the standard prescription protocol for individual drugs. The
default values of sd =1 and mx =24 were considered in our analyses.
MS  may  be  identified  by  text-mining  the  MD  dataset.  For  example,  glucagon-like  peptide-1  receptor  agonist
(GLP-1RA) may be identified by searching for “GLP-1 RECEPTOR AGONIST” in the second order GPI attributed
field.
3.2. “Chaining” Method
The algorithm for the first  approach to extract  and aggregate data for the estimation of duration of treatment is
elaborated below.
1. Merge the following to the MF dataset by patient key:
1.1) date of birth DOB = (db1, db2,...,dbn)
T.
1.2) last available follow-up date L = (l1, l2,...,ln)
T. The extended MF dataset would be of the form.
2. Replace erroneous values of start dates (bi  V  (bi<dbi bi>si bi>li), i = ) with missing values
3. Sort by patient key ascending, chain ID ascending within the same patient, chain sequence descending within the
same chain ID.
4. Set initial values p0 = 0, and approximate individual medication end dates E = (e1, e1,...,en)
T on the basis of the
following rules:
4.1) if stop date is not missing, then end date equals to stop date.
4.2) else, if active flag is “Y”, then end date equals to last follow-up date.
4.3) else, if first unique value of patient key or first unique value of chain ID, and start date is not missing, then end
date equals to start date plus standard prescription duration.
4.4) else, if first unique value of patient key or first unique value of chain ID, and start date is missing, then end date
equals to record creation date plus standard prescription duration.
4.5) else, end date equals to the create date of a previous record.
(Table ?) contd.....
𝑀𝐹1 = {𝑀, 𝑃, 𝐶, 𝐵, 𝑆, 𝐹, 𝐻, 𝐺, 𝐷𝑂𝐵, 𝐿} 
 
∉
 
∧ ∨ ∨
 
1, 𝑛
  𝑀𝐹1:             𝑎) 𝑝𝑖 ≤ 𝑝𝑖+1, 𝑖 = 1, 𝑛                                                                          
 𝑏) ℎ𝑖 ≤ ℎ𝑖+1, ∀𝑖: 𝑝𝑖 = 𝑝𝑖+1   -  post a) sorting 
𝑐) 𝑔𝑖 ≥ 𝑔𝑖+1, ∀𝑖: ℎ𝑖 = ℎ𝑖+1  ∧   𝑝𝑖 = 𝑝𝑖+1 -  post b) sorting   
𝑒𝑖 = 𝕀{𝑏𝑖∉𝑉} ⋅ (𝕀{𝑝𝑖≠𝑝𝑖−1} + 𝕀{ℎ𝑖≠ℎ𝑖−1} − 𝕀{𝑝𝑖≠𝑝𝑖−1} ∙ 𝕀{ℎ𝑖≠ℎ𝑖−1} ) ∙ (𝑠𝑖 ⋅ 𝕀𝑠𝑖∉𝑉 + 𝑙𝑖 ⋅  𝕀𝑓𝑖∈𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉 + (𝑏𝑖 + 𝑠𝑑) ⋅  𝕀𝑓𝑖∉𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉) +
𝕀{𝑏𝑖∈𝑉} ⋅ (𝕀{𝑝𝑖≠𝑝𝑖−1} + 𝕀{ℎ𝑖≠ℎ𝑖−1} − 𝕀{𝑝𝑖≠𝑝𝑖−1} ∙ 𝕀{ℎ𝑖≠ℎ𝑖−1} ) ∙ (𝑠𝑖 ⋅ 𝕀𝑠𝑖∉𝑉 + 𝑙𝑖 ⋅  𝕀𝑓𝑖∈𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉 + (𝑐𝑖 + 𝑠𝑑) ⋅  𝕀𝑓𝑖∉𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉) +
𝕀{𝑝𝑖=𝑝𝑖−1} ⋅ 𝕀{ℎ𝑖=ℎ𝑖−1} ∙ (𝑙𝑖 ⋅  𝕀𝑓𝑖∈𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉 + 𝑠𝑖 ⋅ 𝕀𝑠𝑖∉𝑉 + 𝑐𝑖−1 ⋅  𝕀𝑓𝑖∉𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉), 
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5. Replace values of end dates that falls out of the follow-up interval with last follow-up date.
6. Delete records if start date is missing and create date is greater than stop date. Reduce the dataset to the set of
patients from the cohort of interest and to set of keys of selected drug(s).
7. Merge the following to the PF set by patient key:
7.1) date of birth DOB = (db1, db2,...,dk)
T
7.2)  last  available  follow-up  date  within  the  database  L  =  (l1,  l2,...lk)
T.  The  extended  PF  dataset  would  take  the
following form:
8. Replace erroneous prescription dates (bi  V  (bi<dbi  bi>li), i= ) with missing values.
9. If number of refills is greater than pre-defined maximal number of possible refills or negative or missing, replace
it with zero.
10. Calculate end dates E = (e1, e2,...,ek)
T by the following rules.
10.1) if prescription date is not missing, then end date is equals to standard duration multiplied by the number of
refills plus one and added to prescription date.
10.2) if prescription date is missing, then end date is equals to standard duration multiplied by the number of refills
plus one and added to record creation date.
11. Update end dates as described in Step 5 .
12. Reduce PF1 to the set of patients from the cohort of interest, to the set of patients not in MF2, and to the set of
keys of selected drug(s).
13. Append both datasets by the following values: patient key, record creation date, start / prescription date and end
date, assume that the new dataset MP contain n' records.
where 𝕀{⋅} is an indicator function: 
𝕀{𝑎=𝑏} = {
1, 𝑖𝑓 𝑎 = 𝑏
0, 𝑒𝑙𝑠𝑒        
 𝕀{𝑎∈𝑏} = {
1, 𝑖𝑓 𝑎 ∈ 𝑏
0, 𝑒𝑙𝑠𝑒        
 
𝑒𝑖 = 𝑒𝑖 ⋅ 𝕀{𝑒𝑖≤𝑙𝑖} + 𝑙𝑖 ⋅ 𝕀{𝑒𝑖>𝑙𝑖} 
𝑀𝐹2 = {𝑀𝐹1: 𝑝𝑖 ∈ 𝑃𝑆 ∧ 𝑚𝑖 ∈ 𝑀𝑆 ∧ ¬(𝑏𝑖 ∈ 𝑉 ∧ 𝑐𝑖 > 𝑒𝑖), 𝑖 = 1, 𝑛} 
∉ ∧ 1, 𝑘
𝑟𝑖 = 𝑟𝑖 ⋅ 𝕀{𝑟𝑖<𝑚𝑥} ⋅ 𝕀{𝑟𝑖≥0} ⋅ 𝕀{𝑟𝑖∉𝑉}, 𝑖 = 1, 𝑘 
∧
𝑃𝐹1 = {𝑀, 𝑃, 𝐶, 𝐵, 𝑅, 𝐷𝑂𝐵, 𝐿} 
𝑒𝑖 = (𝑒𝑖 + (𝑟𝑖 + 1) ⋅ 𝑠𝑑) ⋅ 𝕀{𝑒𝑖∉𝑉} + (𝑐𝑖 + (𝑟𝑖 + 1) ⋅ 𝑠𝑑) ⋅ 𝕀{𝑒𝑖∈𝑉} 
𝑃𝐹2 =  {𝑃𝐹1: 𝑝𝑖 ∈ 𝑃𝑆 ∧ 𝑚𝑖 ∈ 𝑀𝑆 ∧ (𝑝𝑖 ∉ 𝑃 ⊂ 𝑀𝐹
2), 𝑖 = 1, 𝑘 } 
?( 𝑒𝑖 = 𝑒𝑖 ⋅ 𝕀{𝑒𝑖≤𝑙𝑖} + 𝑙𝑖 ⋅ 𝕀{𝑒𝑖>𝑙𝑖}, 𝑖 = 1, 𝑘) 
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14.  Calculate  the  number  (cn)  of  distinct  record creation dates  for  each patient,  treat  missing start  dates  by the
following rules:
14.1) if cn is equal to one, then delete the record.
14.2) if cn is greater than one, replace it with record creation date.
15. Sort by patient key ascending, start date ascending within same patient key.
16. For each unique patient key psj PS,j  =  reduce MP  to the set FN
j containing only pi  = psj,  i  = .
Assume that obtained dataset FN j has n''  rows. Set e0  = 0 and calculate selected medication duration for the patient
avoiding double calculations of overlapping intervals.
17. Use medication duration D = (d1, d2,...,du)
T to conduct further research.
3.3. “Continuous” Method
1. Repeat steps 1 and 2 from “chaining” method, then perform step 6, and treat missing values in MF2 as described
in step 14. Assume that obtained dataset MF2 has  instances.
2. Create stop date status variable SI = (st1, st2,...,st )
T on the basis of the following rules:
2.1) if active flag is “Y” and stop date is missing, then stop date status equals to 2.
2.2) if stop date is not missing, then stop date status equals to 1.
2.3) else 0.
3. Sort MF3  by patient key ascending, start date descending within same patient key, stop date status ascending
within the same start dates of the same patient:
𝑀𝐹3 = {𝑃, 𝐶, 𝐵, 𝐸} ⊂ 𝑀𝐹2 
        𝑃𝐹3 = {𝑃, 𝐶, 𝐵, 𝐸} ⊂ 𝑃𝐹2 
𝑀𝑃 = 𝑀𝐹3⋃𝑃𝐹3 
 𝑀𝑃 ∶        𝑎)   𝑝𝑖 ≤ 𝑝𝑖+1, 𝑖 = 1, 𝑛′                                     
                                     𝑏)     𝑏𝑖 ≤ 𝑏𝑖+1, ∀𝑖𝑖: 𝑝𝑖 = 𝑝𝑖+1   -  post a) sorting 
 
∈ 1, 𝑢 1, 𝑛′  
𝐹𝑁𝑗:       𝑑𝑗 = ∑((𝑒𝑖 − 𝑏𝑖) ⋅ 𝕀{𝑏𝑖≥𝑒𝑖−1} + (𝑒𝑖 − 𝑒𝑖−1) ⋅ 𝕀{𝑏𝑖<𝑒𝑖−1} ⋅ 𝕀{𝑒𝑖≥𝑒𝑖−1})
𝑛′′
𝑖=1
 
?̃?
?̃?
𝑠𝑡𝑖 = 2 ⋅  𝕀𝑓𝑖∈𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉 + 1 ⋅ 𝕀𝑠𝑖∉𝑉 + 0 ⋅ 𝕀𝑓𝑖∉𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉 
𝑀𝐹3 = {𝑀, 𝑃, 𝐶, 𝐵, 𝑆, 𝐹, 𝐻, 𝐺, 𝐷𝑂𝐵, 𝐿, 𝑆𝑇} 
  𝑀𝐹3:          𝑎) 𝑝𝑖 ≤ 𝑝𝑖+1, 𝑖 = 1, ?̃?                                                                              
    𝑏) 𝑏𝑖 ≥ 𝑏𝑖+1, ∀𝑖: 𝑝𝑖 = 𝑝𝑖+1   -  post a) sorting 
                               𝑐) 𝑠𝑡𝑖 ≤ 𝑠𝑡𝑖+1, ∀𝑖: 𝑏𝑖 = 𝑏𝑖+1  ∧   𝑝𝑖 = 𝑝𝑖+1  -  post b) sorting   
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4. Set initial value p0 = 0 and approximate individual medication end dates E = (e1, e2,...,e )
T.
4.1) if stop date is not missing, then end date equals to stop date.
4.2) else, if active flag is “Y”, then end date equals to last follow-up date.
4.3) else, if first unique patient key, then end date equals to start date plus standard duration.
4.4) else end date equals to start date of previous record.
5. Perform step 5 from “chaining” method, and steps 7-11.
6. Reduce PF1 to the set of patients from the cohort of interest, to the set of patients not in MF3, and to the set of
keys selected drug(s).
7. Treat missing values in PF2 as described in step 14 of "chaining" method.
8. Append both datasets by the following values: patient key, record creation date, start/prescription date and end
date, assume that the new dataset MP contain  records.
9. Perform steps 15-17 from “chaining” method.
4. REMARKS
Identified erroneous entries are declared as missing in Steps 2, 8, and 9 of “chaining” method. In the Step 14, the
algorithm counts the number of unique creation dates for selected drug(s) at patient level. If obtained number is greater
than one, then missing start dates are replaced with record creation dates. In such a way, a patient is considered to take a
particular drug if the medication records were entered in a systematic manner, otherwise the records with missing start
dates are disregarded.
As an example, the prescription scenario for anti-diabetes drugs for a patient with type 2 diabetes is presented in
Table 1. The treatment was initiated with metformin (METFORMIN HCL) on the 6th of May 2009 and continued until
the  25th  of  April  2011,  when  a  switch  to  GLP-1RA  (LIRAGLUTIDE)  was  made.  With  a  stop  date  for  GLP-1RA
recorded on 14th of December 2011, data show a gap in the treatment till 26th of September 2012, when insulin therapy
begun. However, a patient with diabetes using GLP-1RA is unlikely to have had a nine month long gap in the treatment.
Indeed,  careful  data examination leads to the conclusion that  insulin treatment started on 27th  of  February 2012, as
would be estimated by the algorithm.
As it  was mentioned earlier,  MF was considered as primary data source,  thus if  at  least  one record for selected
drug(s) at patient level is present in the MF, then both methods disregard entities in the PF. However, if there is no
available data in MF table, the methods append data from PF.
Assessment of the first marketing date for a particular drug is an example of additional global consistency audit that
is omitted in the methods’ description. For instance, any start date of GLP-1RA drugs must not be prior to April 2005,
?̃?
𝑒𝑖 = 𝕀{𝑝𝑖≠𝑝𝑖−1} ∙ (𝑙𝑖 ⋅  𝕀𝑓𝑖∈𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉 + 𝑠𝑖 ⋅ 𝕀𝑠𝑖∉𝑉 + (𝑏𝑖 + 𝑠𝑑) ⋅  𝕀𝑓𝑖∉𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉) + 
+𝕀{𝑝𝑖=𝑝𝑖−1} ∙ (𝑙𝑖 ⋅  𝕀𝑓𝑖∈𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉 + 𝑠𝑖 ⋅ 𝕀𝑠𝑖∉𝑉 + 𝑏𝑖−1 ⋅  𝕀𝑓𝑖∉𝐹𝑦 ⋅ 𝕀𝑠𝑖∈𝑉) 
𝑃𝐹2 =  {𝑃𝐹1: 𝑝𝑖 ∈ 𝑃𝑆 ∧ 𝑚𝑖 ∈ 𝑀𝑆 ∧ (𝑝𝑖 ∉ 𝑃 ⊂ 𝑀𝐹
3), 𝑖 = 1, 𝑘 } 
𝑀𝐹4 = {𝑃, 𝐶, 𝐵, 𝐸} ⊂ 𝑀𝐹3 
        𝑃𝐹3 = {𝑃, 𝐶, 𝐵, 𝐸} ⊂ 𝑃𝐹2 
𝑀𝑃 = 𝑀𝐹4⋃𝑃𝐹3 
?̃? 
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the date when first representative (Exenatide) was approved.
5. RESULTS
To evaluate the performance of described methods, we chose to focus on the estimation of the duration of treatment
with two widely used anti-diabetic drugs, namely GLP-1RA and insulin. In the CEMR database 1,861,560 patients were
identified as having been diagnosed with type 2 diabetes mellitus, as inferred from the assigned ICD-9 codes.
5.1. Case Study 1
As the first case study, we consider a randomly selected patient from the CEMR database, whose relevant treatment
details are shown in Table 3. The treatments with EXENATIDE and INSULIN GLARGINE started on the 18th of June
2007. The treatment with EXENATIDE was terminated on the 7th of January 2008, while INSULIN therapy continued
until the last recorded follow-up date on the 24th of January 2008 (notice that the treatment is flagged as active, “Y”). In
this case, the “chaining” and “continuous” methods produce the same estimates for the durations of the two treatments.
Specifically, the estimates corresponding to insulin and GLP-1RA are 7.2 and 6.7 months, respectively.
Table 3. Snapshot of MF table-combining therapies. Patient’s last follow-up date was identified as 24 January 2008.
GPI category 4 Medication
key (M)
Patient key
(P)
Create date
(C)
Start date
(B)
Stop
date (S)
Active
flag
(F)
Chain ID
(H)
Chain
seq
(G)
Enddate
(“chaining”)
Enddate
(“continuous”)
INSULIN
GLARGINE
682327 15219411 18-Jun-07 18-Jun-07 N 136664321 0 20-Jun-07 20-Jun-07
EXENATIDE 12670645 15219411 18-Jun-07 18-Jun-07 N 136664552 0 17-Oct-07 15-Oct-07
INSULIN
GLARGINE
1096062 15219411 20-Jun-07 20-Jun-07 N 136664321 1 7-Jan-08 7-Jan-08
EXENATIDE 12670548 15219411 17-Oct-07 15-Oct-07 N 136664552 1 7-Jan-08 7-Jan-08
INSULIN
GLARGINE
1096062 15219411 7-Jan-08 7-Jan-08 Y 136664321 2 24-Jan-08 24-Jan-08
EXENATIDE 12670548 15219411 7-Jan-08 7-Jan-08 7-Jan-08 N 136664552 2 7-Jan-08 7-Jan-08
5.2. Case Study 2
As an insightful case study, we consider a patient whose relevant treatment details are shown in Table 4. Since all of
the records shown have the same chain ID it can be concluded that in the period from the 23rd of April of 2010 until the
13th  of  March 2013 the  patient  was  alternating  between two therapies,  namely  with  GLP-1RA (EXENATIDE) and
insulin  (INSULIN  GLARGINE).  This  example  illustrates  the  importance  of  chain  ID  information,  as  readily
corroborated by comparing the predicted therapy end dates using the “chaining” and “continuous” methods (per record
estimates are shown in the two rightmost columns of Table 4). The latter disregards chain ID information, it implicitly
assumes that EXENATIDE was taken continuously from the 23rd of April 2010 until the 27th of April 2011, with the last
prescription date being the 28th of March 2011. However, treatment with EXENATIDE was terminated on the 29th of
December 2010 when a switch to insulin was made. Treatment with insulin continued until  the 28th  of March 2011
when a switch back to EXENATIDE appeared. This complex and frequent pattern of therapy alteration leads to vastly
different treatment duration estimates when chain ID information is used (“chaining”) and when it is not (“continuous”).
For  example,  in  this  particular  case,  “continuous”  approach  estimates  the  total  duration  of  insulin/  EXENATIDE
treatment to be 5.7/ 28.9 months, compared to 26.5/ 12.1 months estimated by “chaining” method.
Table 4. Snapshot of MF table-switching between therapies. Patient’s last follow up date was identified as 13 March 2013.
GPI category 4 Medication
key (M)
Patient key
(P)
Create date
(C)
Start date
(B)
Stop
date
(S)
Active
flag
(F)
Chain ID (H) Chain
seq
(G)
Enddate
(“chaining”)
Enddate
(“continuous”)
EXENATIDE 1523512 64832053 23-Apr-10 23-Apr-10 N 1002923273 0 29-Dec-10 28-Mar-11
INSULIN
GLARGINE
682327 64832053 29-Dec-10 29-Dec-10 N 1002923273 1 06-Jan-11 06-Jan-11
INSULIN
GLARGINE
682327 64832053 06-Jan-11 06-Jan-11 N 1002923273 2 28-Mar-11 18-Dec-12
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GPI category 4 Medication
key (M)
Patient key
(P)
Create date
(C)
Start date
(B)
Stop
date
(S)
Active
flag
(F)
Chain ID (H) Chain
seq
(G)
Enddate
(“chaining”)
Enddate
(“continuous”)
EXENATIDE 1523512 64832053 28-Mar-11 28-Mar-11 N 1002923273 3 18-Dec-12 27-Apr-11
INSULIN
GLARGINE
682327 64832053 18-Dec-12 18-Dec-12 N 1002923273 4 13-Mar-13 13-Mar-13
INSULIN
GLARGINE
682327 64832053 13-Mar-13 13-Mar-13 Y 1002923273 5 13-Mar-13 13-Mar-13
5.3. General Analysis
Given our focus on GLP-1RA and insulin, to facilitate further analysis, from the cohort of all T2DM patients we
selected those who at any point in their medical history received treatment with either of the two drugs of interest. Text
mining of drug names in MD table revealed various insulin regimens as well as related devices (e.g. insulin syringe). To
quantify  the  result,  we  found  that  approximately  30%  of  the  patients  in  the  T2DM  cohort  received  at  least  one
prescription  for  insulin  drug.  Interestingly,  a  large  number  of  patients  (~25,000)  were  found  to  have  received
prescriptions for insulin devices but not for insulin therapy itself. Further exploration on these patients revealed that the
average duration of use of these devices in this patient group was 21 months (Table 5), strongly suggesting that there
was  an  accompanying  insulin  therapy  which  was  not  recorded  in  the  stored  EMRs.  This  conclusion  is  further
corroborated by the finding that the mean glycated haemoglobin (HbA1c) level for these patients was measured to be
7.8% on the date of the first record associated with the device.
Table 5. Summary statistics on the estimated duration in months of treatment with specific medications in T2DM cohort
(n=1,861,560) by “chaining” and “continuous” methods, and the difference in the estimated duration between “chaining” and
“continuous” methods.
“Chaining” method “Continuous” method “Chaining” - “continuous”
n (%) Mean
(sd)
(min,
max)
Median
(IQR)
n (%) Mean
(sd)
(min,
max)
Median
(IQR)
n (%) Mean
(sd)
(min,
max)
Median
(IQR)
Insulin +
device
588923
(32)
32.5 (35) (0,
657.8)
21.6 (6.5,
46.8)
591441
(32)
32.7
(34.9)
(0,
657.8)
21.8 (6.3,
47.4)
588923
(32)
-0.2
(4.8)
(-167.8,
183.4)
0 (0, 0)
Insulin only 563293
(30)
32.0
(34.9)
(0,
657.8)
20.8 (6.1,
45.8)
566014
(30)
32.2
(34.8)
(0,
657.8)
21.0 (6,
46.5)
563293
(30)
-0.3 (5) (-167.8,
176.9)
0 (0, 0)
no Insulin, but
device
25536 (1) 21.2
(21.5)
(0,
196.8)
14.3 (4.8,
30.9)
25386 (1) 21.2
(21.9)
(0,
190.7)
14.1 (4.4,
31.1)
24910 (1) -0.2 (5) (-131.8,
183.4)
0 (0, 0)
GLP1RA 113416
(6)
18.3
(19.4)
(0,
110.7)
11.7 (3.9,
26)
114316
(6)
19.2
(21.0)
(0,
111.7)
11.7 (3.5,
27.4)
113416
(6)
-1.0
(7.6)
(-103.9,
95.4)
0 (0, 0)
Exenatide 73326 (4) 18.8
(20.2)
(0,
110.7)
11.6 (3.9,
26.5)
74060 (4) 18.8
(21.4)
(0,
111.2)
10.6 (3.1,
26.7)
73326 (4) -0.2
(8.4)
(-97.0,
95.4)
0 (0, 0)
Liraglutide 56406 (3) 12.5
(11.9)
(0, 56.2) 8.6 (3, 19) 56907 (3) 12.7
(12.4)
(0, 56.2) 8.3 (2.5,
19.5)
56406 (3) -0.3
(4.0)
(-49.5,
47.5)
0 (0, 0)
Albiglutide 14 (0) 1.3 (0.5) (1, 2.4) 1 (1, 1.9) 15 (0) 1.3 (0.5) (1, 2.4) 1.0 (1, 1.9) 14 (0) 0 (0) (0, 0) 0 (0, 0)
In patients with treatment duration ≥2 Months
Insulin +
device
518000
(28)
36.8
(35.2)
(2,
657.8)
26.4 (11.1,
51.6)
518318
(28)
37.1
(35.0)
(2,
657.8)
26.8 (11.2,
52.3)
516808
(28)
-0.3
(4.9)
(-167.8,
176.9)
0 (0, 0)
Insulin only 492992
(26)
36.4
(35.2)
(2,
657.8)
25.8 (10.7,
50.8)
493494
(27)
36.7
(35.1)
(2,
657.8)
26.3 (10.9,
51.6)
491847
(26)
-0.4
(5.2)
(-167.8,
176.9)
0 (0, 0)
no Insulin, but
device
22085 (1) 24.3
(21.5)
(2,
196.8)
17.8 (8,
34.1)
21628 (1) 24.7
(21.9)
(2,
190.7)
18.0 (8,
34.8)
21342 (1) -0.5
(4.1)
(-131.8,
65.3)
0 (0, 0)
GLP1RA 96458 (5) 21.3
(19.6)
(2,
110.7)
14.9 (6.8,
29.3)
94972 (5) 22.9
(21.3)
(2,
111.7)
15.7 (6.9,
31.8)
94372 (5) -1.5
(7.8)
(-103.9,
95.4)
0 (0, 0)
Exenatide 62538 (3) 21.8
(20.4)
(2,
110.7)
14.7 (6.6,
30.4)
60228 (3) 22.9
(21.7)
(2,
111.2)
15.0 (6.5,
32.1)
59812 (3) -0.8
(8.0)
(-97.0,
95.4)
0 (0, 0)
Liraglutide 45432 (2) 15.3
(11.6)
(2, 56.2) 12 (5.8,
22.1)
44344 (2) 16 (12.2) (2, 56.2) 12.5 (5.9,
23.4)
43991 (2) -0.6
(3.9)
(-49.5,
43.9)
0 (0, 0)
Albiglutide 2 (0) 2.2 (0.2) (2.1, 2.4) 2.2 (2.1,
2.4)
2 (0) 2.2 (0.2) (2.1, 2.4) 2.2 (2.1,
2.4)
2 (0) 0 (0) (0, 0) 0 (0, 0)
The number of patients receiving insulin and GLP-1RA, and the corresponding treatment duration estimates (in
months)  produced  by  our  algorithms  (“chaining”  and  “continuous”),  are  summarized  in  Table  5.  Different  insulin
regimens were treated jointly, as we found that any finer level of detail is poorly recorded in the database. As regards to
(Table ?) contd.....
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GLP-1RA treatment, only three different GLP-1RA drugs (namely, Exenatide, Liraglutide, and Albiglutide) have been
used. Being new to the market (introduced in 2014), only limited data was available for Albiglutide treatment.
The estimate of the proportion of patients identified as having received specific individual drugs was found to be
very similar using both the “chaining” approach, as well as the non-chain ID based alternative “continuous” approach,
as  shown  in  Table  5.  The  corresponding  values  of  the  key  statistics  –  namely  the  mean,  standard  deviation  (SD),
median, and the interquartile range (IQR)- of the respective estimates of the duration of treatment with individual drugs
were also similar. The average differences in the estimated duration of treatment with insulin only and GLP-1RA drugs
were 0.3 month and 1 month respectively. There were no differences at the median levels. Separate analyses for patients
with minimum 2 months of treatment duration with individual therapies also revealed the same results. However, it is
important to note that although the cumulative statistics of the estimated treatment durations with different therapies
were not significantly different, we did find notable differences in the minimum and maximum duration estimates for
specific patient subgroups, as evident from (Table 5).
6. DISCUSSION
In  this  work  we  addressed  a  number  of  challenging  data  mining  related  issues  while  extracting  patient-level
longitudinal information on prescription patterns and medication usages from large relational databases (our data set
comprises more than a billion records). There are several key contributions of note. Firstly we identified the specific
challenges  which  automatic  methods  must  deal  with  in  the  processing  of  this  complex  voluminous  data.  We
corroborated our arguments using analysis of real-world EMRs and discussed the importance and the implications of
being able to handle erroneous and incomplete longitudinal information. Secondly, we introduced two methods for the
estimation  of  the  duration  of  treatment  with  specific  drug(s)  in  the  presence  of  the  aforementioned  challenges.
Developed sequentially ordered case by case rules were presented mathematically. To the best of our knowledge, no
robust  algorithmic  approach  has  yet  been  reported  to  evaluate  treatment  duration  with  individual  medications  in
multiple treatment scenario [22, 27].
We have described two algorithmic approaches to estimate treatment duration on the individual record level. First
method (“chaining”) relies on specific chaining fields of medication information, while second approach (“continuous”)
does not use chain related information and employs only chronological record information instead. Our results on the
large Centricity EMR database show that the two approaches do not produce significantly different results on average at
population level. However, when examined in detail, the “chaining” method could identify the treatment alterations
longitudinally and was shown to be more robust at individual patient level. Furthermore, treatment duration estimates
from the “continuous” approach are more sensible to the set of selected medications. The difference between methods is
particularly prominent in studies involving multiple drugs as opposed to single drug therapies or focusing on the order
of treatment initiation [48, 49].
Our  study  highlighted  the  potential  risk  of  underestimating  the  duration  of  treatment  when  EMR  data  is  used
directly, due to erroneous or incomplete data emerging from omissions in the data entry process, appointments missed
by  patients,  typographical  errors,  or  numerous  others.  Both  proposed  algorithms  robustly  handle  these  challenges
whenever is possible, estimating values of the missing or erroneous entries. Importantly, being rule based, the decisions
of our algorithms are readily interpretable by humans and lend themselves to effortless use by medical professionals not
necessarily proficient in data mining and related disciplines. Both approaches implement two fact datasets available in
the Centricity EMRs, however algorithms are easily adjusted in case of only one available dataset.
CONCLUSION
This study discusses the challenges in exploring the prescription / medication patterns for individual patients in
large primary / ambulatory care electronic databases, and introduces two algorithmic approaches for robust estimation
of treatment duration with individual drug(s). We have demonstrated that implementing chaining fields of medication
information additionally improve the quality of estimates. Given the importance of extracting medication information
appropriately in pharmaco-epidemiological studies based on real world data, the proposed algorithms has the potential
to significantly contribute to the analytical quality aspects in the future EMR based clinical and epidemiological studies.
LIST OF ABBREVIATIONS
EMR = Electronic Medical Rerecords
CEMR = Centricity Electronic Medical Rerecords
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T2DM = Type 2 Diabetes
MD = Medication Dimension
MF = Medication Fact
PF = Prescription Fact
GPI = Generic Product Identifier
ID = Identification
DOB = Date of Birth
SD = Standard Deviation
IQR = Interquartile Range
GLP-1RA = Glucagon-Like Peptide-1 Receptor Agonist
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